ProPhase is proud to partner with companies that also seek to transform measurement science and improve outcomes in clinical trials for all stakeholders. The purpose of our partnerships is to deliver a comprehensive suite of measurement-related services by integrating best-in-class approaches for the benefit of both our Sponsor and CRO clients.

Scale Licensing


The leading publisher of scientifically validated assessments for more than 30 years, Multi-Health Systems Inc. (MHS) serves clients in educational, clinical, corporate, public safety, government, military, pharmaceutical, and research settings. MHS has grown to become an international company with products sold in more than 75 countries and translated into over 50 languages.

MHS publishes an extensive line of clinical products that are specially designed to help clinicians and mental health professionals assess children, adolescents, and adults for the possible presence and severity of psychological disorders. MHS has provided the psychological, public safety, and corporate community with leading products such as the Conners suite of ADHD assessments, the Emotional Quotient Inventory (EQ-i 2.0®) and the Positive and Negative Syndrome Scale (PANSS).

MHS has granted ProPhase an exclusive license to electronically adapt the PANSS on eCOA devices and similar electronic platforms

For more information about MHS, please visit



With more than 80 years of experience in the assessment field, Pearson’s Clinical Assessment group offers innovative and comprehensive products and services to meet our varied customers’ needs. Pearson has taken a leadership role in assessment that has resulted in a continuous timeline of many innovations. They concentrate on merging innovation with quality test design to develop increasingly more effective tools for children and adults, educators and clinicians.

Pearson is particularly noted for their gold-standard assessment contributions in cognitive/ability, memory, neuropsychology, behavior, personality/psychopathology, achievement and speech/language. Noted brands include the Wechsler, Millon, and Beck families of products, as well as other widely used instruments such as the RBANS, D-KEFS, Vineland-II, Bayley-III, BASC, CELF, and PLS.

ProPhase and Pearson have an established Master Services Agreement enabling an expedited licensing and content acquisition process in clinical trials, as well as authorization to commission translations and linguistic validation of scales and their components, upon request.

For more information about Pearson’s Clinical Assessment Group, please visit


Medication Adherence


AiCure’s mission is to equip patients, researchers and providers with the intelligence to understand the exact link between medication and health.

AiCure has developed artificial intelligence solutions to directly confirm medication ingestion. The patented technology identifies the patient and the medication and uses sophisticated features to detect diversion and identify duplicate enrollment. The software as a service (SaaS) model maximizes flexibility and scalability. By reducing risk in clinical trials and optimizing treatment in population health, we provide direct results based on accurate real-time adherence data.

ProPhase has worked with AiCure’s leadership for several years to better understand the challenges of medication adherence as a critical precondition for meaningful outcome measurement. ProPhase and AiCure are currently working on a large Phase II schizophrenia program, among other initiatives.

For more information about AiCure, please visit



The PANSS Institute (TPI) is a nonprofit organization whose mission is to support the validity and reliability of the Positive and Negative Syndrome Scale (PANSS), and to train raters in the optimal use of the PANSS. The PANSS is accepted as the most widely used gold standard primary outcome measure for psychotic disorders in global clinical trials. TPI was established by the developers of the PANSS–clinicians, scientists, and psychometricians—to aid researchers, caregivers, and community groups working with populations suffering from mental illness worldwide. TPI trains and educates clinicians and community healthcare providers in patient assessment and treatment efficacy in order to improve mental health outcomes. They also seek to further the quality and the quantity of psychiatric research with an emphasis on novel approaches, evidence-based medicine, local relevance, and integrating results into current practice.

ProPhase and TPI have a long-standing and deep partnership. Both ProPhase and TPI share a commitment to developing and maintaining the highest standards in the administration and use of psychometric instruments in clinical trials. TPI obtained 501c3 nonprofit status in 2012 and is organized exclusively for educational, research and charitable work.

Learn more about the mission and resources available at The PANSS Institute at



The Health and Development Foundation (HDF), formerly known as Healthy Russia, is a non-profit, non-governmental organization acting in the field of development and conducting programs aimed at public health improvement and behavior change in Russia. HDF has 10 years of experience in designing and implementing comprehensive educational and outreach programs to improve the health and healthy lifestyle skills of Russians, including programs targeting health care professionals.

The work of the Health and Development Foundation has a strong mHealth focus, using mobile technologies in communicating with vulnerable populations, such as HIV+ IDUs, and in the education of health care providers. In addition, mHealth technologies are used to help train medical professionals to carry out and interpret data for clinical trials.

Most recently, ProPhase partnered with HDF to carry out its self-funded psychometric validation study of the new Russian translation of the PANSS. The study enrolled 450 subjects (inpatients, outpatients, and healthy controls) and led to the publication of a fully validated Russian PANSS version for use with Russian-speaking patients.

To learn more about the mission and current projects of Healthy Russia, visit


Computerized Cognition Testing


Cambridge Cognition is a global science and technology company, developers of the world’s leading neuropsychological tests and providers of expert scientific services. They support thousands of universities, pharmaceutical companies, biotechs and healthcare providers with products and services to improve mental health research, accelerate the development of safe and effective treatments and detect the earliest signs of cognitive impairment in patients.

Their computerized neuropsychological assessment products, CANTAB, are used in research, healthcare and clinical trials and have been validated by over 1,600 peer-reviewed publications. The Cantab range includes products for:

    • • Academic Research – Promoting products for use in Academic Research since 2002
    • • Clinical Drug Trials – GCP compliant product for use in clinical trials since 2004
    • • Healthcare Technology – Delivering science through Cloud technology direct to patient

The Cambridge Neuropsychological Test Automated Battery (Cantab) was originally developed at Cambridge University in the 1980’s by renowned neuroscientists, Professors Barbara Sahakian and Trevor Robbins. The neuropsychological tests used in Cantab technology have been continually enhanced by Cambridge Cognition since 2002. The computer-based cognitive assessment system is designed for specific use in clinical research studies and is administrated to subjects using a touchscreen computer. Today, Cantab technology is being used to assess cognition in hundreds of leading research institutions worldwide and has been backed by over 1,600 peer-reviewed articles. It is suitable for assessing young and old subjects, is culture and language independent and highly sensitive to disorder related impairment, pharmacological manipulation and cognitive enhancement.

ProPhase has worked with Cambridge Cognition on delivering an integrated approach to comprehensive clinical assessment in multiple indications, including psychiatry, neurology, and rare/orphan diseases.

For more information on Cambridge Cognition’s experience and services, visit